Prisinformation från TradingView

Bolagspresentation:

Nyhetsflöde Arocell

Related articles:
2/23/2024 1:15:25 PM - AroCell Q4: Nearing positive operating cash flow - Redeye - Redeye leaves its estimates and valuation untouched following the report. However, our gross margin assumptions might be reconsidered (downward) if the coming quarters do not show better gross margin development.
11/6/2023 9:37:51 AM - AroCell Q3: Developing well, but looking over long-term forecasts - Redeye - Redeye continues to see good cost control and highlights that the low y/y sales growth can be partly explained by a shift in revenue recognition in Q3. While we argue that the company is developing well, we reconsider our long-term sales forecast (contingent on a US launch of UBC Rapid/TK210 ELISA) and make downward changes.
8/28/2023 1:35:07 PM - AroCell Q2: An unrecognized fully financed growth case - Redeye - Redeye emphasises that AroCell continues to go unnoticed by the stock market, with stable sales development, ongoing geographical expansion, and good cost control. Essentially, the Q2 financials were in line with our estimates, and we make only minor changes to our forecasts.
5/4/2023 7:30:07 AM - AroCell Q1: Solid foundation in the making - Redeye - Redeye sees an unrecognized business with stable sales development, ongoing geographical expansion, and good cost control. Following the report, which came in line more or less with our expectations, we reiterate our stance on AroCell flying under the radar with its product portfolio. At current levels, the stock market fails to see the core-business developments since the 2021 FDA withdrawal of TK210 ELISA and the cheapness of the stock.
2/24/2023 8:12:11 AM - AroCell Q4: Steady operations - Redeye - Redeye notes a quarter showing continuing sales growth for AroCell with good cost control. We slightly up our sales estimate for 2023e and lower our WACC following a review or Redeye Quality Rating, resulting in upwards changes to our fair value range.
10/31/2022 7:47:31 AM - AroCell Q3: Cost synergies more apparent, continued sales growth - Redeye - Redeye continues to be positively surprised by the cost improvements by AroCell and believes the IDL Biotech's cost synergies to be in full effect. Sales came in higher than our expectations and OPEX lower than our estimates. We reiterate our fair value range.
8/18/2022 7:11:18 AM - AroCell Q2: Good cost control, somewhat lower sales - Redeye - Redeye returns with a more detailed take on the Q2 report and notes lower costs than expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E sales somewhat. We reiterate our fair value range.
6/11/2022 10:38:35 AM - AroCell - VD Anders Hultman gästar podcast - Anders Hultman, VD AroCell, intervjuas av Daniel Ljungström om bolaget, dess erbjudande och framtidsplaner. AroCell vill erbjuda lösningar som gör att det snabbare går att avgöra om behandling av vissa cancerformer är effektiv. Anders beskriver bolaget och de problem de löser närmare. De pratar också om marknaden för Medtech i allmänhet, hur Anders ser på den framåt samt hur han planerar att navigera AroCell i den.
5/16/2022 8:42:37 AM - NeoDynamics: Cash in the Bank but Slower Sales Ramp-up - Redeye - Redeye returns with a more in-depth take on NeoDynamics following the Q1 report. In this update, we re-consider our financial projections on the basis of a prolonged US launch and slower market ramp-up in the EU than previously anticipated. Accordingly, we lower our Fair Value Range.
5/6/2022 4:48:25 AM - Attana planerar flytt av produktion av förbrukningsvaror till Arocell - Attana har inlett diskussioner om flytt av produktion av förbrukningsvaror som sensorchip och reagenser till in vitro-diagnostikbolaget Arocell. Det framgår av ett pressmeddelande.
5/3/2022 8:03:12 AM - AroCell Q1’22: Encouraging sales development and good cost control - Redeye - Redeye embraces AroCell’s Q1’22 report, demonstrating good cost control and higher sales than expected (albeit still in small figures). We slightly up our Base Case following the report - our fair value range suggests a hefty upside from today’s share price levels, but we emphasize the market volatility and an overhang from guarantors’ commitments from the rights issue.
2/28/2022 9:12:13 AM - AroCell: Q4’21 review - Redeye - Redeye returns with a more detailed take on the Q4 report with some estimate changes, primarily for the two coming years. We reiterate our fair value range, suggesting a hefty upside from today’s share price levels, but emphasize the market volatility and an overhang from guarantors’ commitments from the rights issue.
2/24/2022 10:29:00 AM - AroCell Q4: Comments on the quarterly report - Redeye - Redeye notes a relatively decent quarter for AroCell, which is currently trading under our Bear Case with an EV reflecting considerably low sales multiples for the IDL Biotech product portfolio for the coming years. While the eventual recognition of this could act as a catalyst for the stock, we emphasize the rights issue’s outcome with a probable wet-blanket effect on the share price performance going forward.
2/18/2022 8:30:07 PM - AroCell: Redeye resumes coverage following rights issue - Redeye - Redeye resumes its coverage of AroCell following the rights issue adding SEK 86m (before transaction costs) to the company's balance sheet. We adjust our fair value range according to the new number of shares and cash position.
2/9/2022 9:31:18 AM - Attana diskuterar samarbete med Arocell - Attana har inlett en diskussion om ett nytt samarbete med in vitro diagnostiskbolaget Arocell, enligt ett pressmeddelande. Samarbetet som diskuteras syftar till ett utbyte av värdefull kunskap inom kvalitet och produktutveckling samtidigt som Arocells biomarkörer på sikt kan nyttjas på Attanas instrument.
12/17/2021 10:16:11 AM - AroCell: Rights issue announced – we pause our coverage - Redeye - Redeye gives a short comment on the announced rights issue and pauses its coverage.
11/15/2021 12:48:36 PM - AroCell Q3: First quarter with acquired IDL Biotech - Redeye - Redeye has a relatively neutral take on AroCell’s Q3 report, though we make some minor upwards adjustments to sales expectations and overlook our costs assumptions. Specifically, we believe we have had a too harsh take on administrative expenses, a line item that should see positive change following the acquisition of IDL Biotech. The changes to our estimates do not imply a retake to the valuation – our Base Case remains at SEK 3.5 per share.
11/2/2021 9:59:24 AM - AroCell: A Closer Look at the Acquisition - Redeye - Redeye returns with a more in-depth view on AroCell’s acquisition of IDL Biotech, seeing a new case with more substantial commercial opportunities in the short to medium term, despite TK210 ELISA’s US prospects taking a beating. We reassess our estimates and update our fair value range, which is considerably higher than the current share price. Still, skepticism toward the stock is likely to persist owing to the recent FDA disappointment.
10/28/2021 7:20:25 AM - AroCell: Strategy Update from 27th of October - Redeye - Arocell held a Strategy Update on the 27th of October. Check out the full replay in case you missed it.
8/31/2021 11:58:45 AM - AroCell: Comments on the Q2 report - Redeye - Redeye comments on the Q2 report and shortly discusses the two major events during and after the quarter, setting a new direction for AroCell. It has been a turbulent couple of months for the company and the stock, and we await a communicated new strategy with the IDL Biotech merger before we present a more detailed review of the case.
8/12/2021 8:58:35 AM - Arocell: FDA application withdrawal threw the share out the window - Redeye - Redeye is surprised by the recently announced withdrawal of AroCell’s FDA application, which effectively cut its share price in half. The decision based on the FDA’s conclusion that there is no predicate device to base its application upon puts AroCell several steps back for its breast cancer indication.
8/10/2021 3:20:20 PM - Arocell drar tillbaka FDA-ansökan, aktien faller med 49 procent - Biokemibolaget Arocell har efter en diskussion med det amerikanska läkemedelsverket FDA har dragit slutsatsen att den predicate device som valdes för bolagets 510(k)-ansökan inte är möjlig givet den avsedda användningen. Det framgår av ett pressmeddelande.
7/21/2021 7:41:27 AM - IDL Biotech avnoteras från Spotlight med sista handelsdag den 4 augusti - Spotlight Stock Market har efter ansökan från diagnostikbolaget IDL Biotech beslutat att avnotera bolagets aktier. Sista handelsdag på Spotlight blir den 4 augusti. Det framgår av ett marknadsmeddelande.
7/20/2021 2:54:41 PM - IDL Biotech ansöker om avnotering från Spotlight efter uppköp - Diagnostikbolaget IDL Biotech har ansökt om avnotering från Spotlight Stock Market. Detta sedan Arocell har nått 95,92 procents ägande i bolaget efter uppköpsbudet som lades i maj.
7/6/2021 12:06:49 PM - Arocell: Fusion with IDL Biotech - Redeye - Redeye will return with an update following the recent successful fusion with IDL Biotech last week. With an acceptance rate translating to some 96% of the shares and votes in IDL Biotech, and the transaction soon to be fully completed, we now await further discussions with AroCell’s management in regard to its strategy going forward. Hence, we will re-assess the case and come back later during the summer with a more detailed take on AroCell and its fusion.
5/28/2021 6:18:56 AM - Oberoende budkommittén rekommenderar budet från Arocell på IDL Biotech - Diagnostikbolaget IDL Biotechs oberoende budkommitté rekommenderar aktieägarna att tacka ja till budet från Arocell.
5/24/2021 9:30:04 AM - Arocell: Expansion to prostate cancer in the EU - Redeye - Redeye endorses AroCell’s clinical widening of its TK210 ELISA kit for the indication of prostate cancer (in the EU). The expansion of intended use supported by the clinical data on said indication is well in line with our expectations and take on the case. We will return with an update focusing on its bid on IDL Biotech, where the matter will be addressed more thoroughly.
5/14/2021 6:17:08 AM - Arocell Q1: Comments on the report - Redeye - Redeye highlights the Q1 report takeaways and sees an exciting year ahead with two significant events anticipated to play out: FDA clearance for its TK210 ELISA kit as well as the stock-for-stock merger with diagnostics company IDL Biotech.
5/10/2021 3:48:33 PM - Arocell: Planned stock-for-stock merger with IDL Biotech - Redeye - Redeye comments AroCell’s bid on diagnostics company IDL Biotech. The decision to venture into M&A activities came as a surprise to us and requires further digging before providing a more in-depth take on the news and its impact on the now altered case. Still, we summarize the announcement following a meeting with management.
5/10/2021 6:08:56 AM - Arocell lägger bud på IDL Biotech med 56 procent premie - Arocell har lagt ett uppköpserbjudande på samtliga aktier i IDL Biotech värt cirka 237 miljoner kronor. Det framgår av ett pressmeddelande.
4/19/2021 6:13:38 AM - Arocell: Resumed FDA review - Redeye - Redeye welcomes the resumed FDA review of AroCell's 510(k) application – an anticipated event where the FDA's final decision should be announced within the coming 90 days. An eventual approval would be significant for the company and an important step towards its ambitions. The share is currently stretching beyond our Base Case of SEK 5 after a hastily upwards momentum. However, a timeline of 90 days until eventual approval could sustain momentum but a cooldown, too, is likely, we judge.
4/15/2021 10:03:41 AM - Arocell: Strengthened clinical data on prostate cancer - Redeye - Redeye endorses the new study supporting TK1 as a predictive biomarker for prostate cancer. We are encouraged in the strengthening of data for this specific indication and expect AroCell to accelerate further with this cancer type once it has progressed with its focus on breast cancer.
1/11/2021 9:12:06 AM - Arocell byter vd - finanschefen tar över - Biokemibolaget Arocell har utsett finanschefen Anders Hultman till ny vd när tidigare vd Michael Brobjer lämnar uppdraget.
11/19/2020 7:07:11 AM - Arocell rörelseförlust ökar i tredje kvartalet - Arocell redovisar som planerat inga intäkter under tredje kvartalet jämfört med samma period året innan. Rörelseförlusten ökade något.
11/13/2020 9:49:10 AM - Ny artikel visar att mätning av TK1 kan skilja Mycoplasma-lunginflammation från luftvägsinfektioner - Arocell - Arocell lyfter fram att en nyligen publicerad artikel i Journal of Immunological Methods visar att mätning av TK1-koncentrationen kan skilja Mycoplasma-lunginflammation från andra bakterieinfektioner. Det framgår av ett pressmeddelande.
10/30/2020 9:36:46 AM - Arocell får tidslinje för FDA-ansökan försenad på grund av pandemin - Arocells inlämnade 510(k)-ansökan till det amerikanska läkemedelsverket, FDA, kommer att få sin tidslinje försenad på grund av covid-19-pandemin. Det framgår av ett pressmeddelande.
10/26/2020 9:36:43 AM - Åtta aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på åtta nya 52-veckorshögsta på Stockholmsbörsens listor.
10/15/2020 8:44:54 AM - Sex aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på sex nya 52-veckorshögsta på Stockholmsbörsens listor.
10/14/2020 8:35:27 AM - 17 aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på 17 nya 52-veckorshögsta på Stockholmsbörsens listor.
10/2/2020 8:34:40 AM - Sex aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på sex nya 52-veckorshögsta på Stockholmsbörsens listor.
10/1/2020 8:39:58 AM - 12 aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på 12 nya 52-veckorshögsta på Stockholmsbörsens listor.
9/30/2020 8:37:13 AM - Åtta aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på åtta nya 52-veckorshögsta på Stockholmsbörsens listor.
9/22/2020 3:09:35 PM - Arocell kommer uppdatera ansökan till FDA inom några veckor - Arocell meddelar att man haft dialog med amerikanska Food and Drug Administration (FDA) angående den 510(k) submission som företaget skickade in den 26 maj 2020.
8/21/2020 11:55:10 AM - Arocell har fått ett godkännandebeslut för sin europeiska patentansökan - Arocell har fått en godkännandebeslut för sin patentansökan av bolagets egenutvecklade monoklonala antikroppar från det europeiska patentverket, EPO. Det framgår av ett pressmeddelande.
8/20/2020 6:25:53 AM - Arocell redovisar som väntat små förändringar av resultatet - Arocell redovisar ingen omsättning och små förändringar av resultatet.
8/6/2020 8:08:01 AM - Arocell initierar klinisk studie inom prostatacancer med universitet - Arocell har inlett ett nytt samarbete med University of Rome la Sapienza för en klinisk studie inom prostatacancer, enligt ett pressmeddelande.
8/6/2020 5:11:21 AM - Arocell utser Gunnar Steineck till interim medicinsk chef - Bioteknikbolaget Arocell har utsett professor Gunnar Steineck till interim medicinsk chef. Han har en lång erfarenhet som urolog/onkolog och ha tidigare varit styrelsemedlem i Arocell. Tjänsten tillträds idag den 6 augusti. Det framgår av ett pressmedelande.
8/5/2020 8:35:09 AM - Tio aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på tio nya 52-veckorshögsta på Stockholmsbörsens listor.
8/4/2020 8:35:09 AM - 17 aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på 17 nya 52-veckorshögsta på Stockholmsbörsens listor.
7/30/2020 8:40:36 AM - Åtta aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på åtta nya 52-veckorshögsta på Stockholmsbörsens listor.
7/29/2020 8:34:56 AM - Sju aktier har hittills i dag noterat nytt 52-veckorshögsta på Stockholmsbörsen - Hittills i dag har det bjudits på sju nya 52-veckorshögsta på Stockholmsbörsens listor.
7/21/2020 7:21:42 AM - Arocell har beviljats patent i Japan - Arocell meddelar idag att man beviljats ett patent i Japan avseende bolagets egenutvecklade monoklonala antikroppar som används för att bestämma koncentrationen av tymidinkinas 1 i serumprover, "Monoclonal anti-TK1 antibodies". Det framgår av ett pressmeddelande.